EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis

Marcelo Kugelmas, Mazen Noureddin, Nadege Gunn, Kimberly Brown, Zobair Younossi iD, Manal Abdelmalek, Naim Alkhouri

Liver International · 2023

DOI: 10.1111/liv.15555 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Liver International, 2023. Verfasst von Marcelo Kugelmas und 6 weiteren Autor:innen. Beteiligte Einrichtung: South Denver Gastroenterology, Englewood, Colorado, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is ongoing recognition of the burden of non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH), with fibrosis being the most important histological feature that is associated with progression to cirrhosis and the occurrence of major adverse liver outcomes. Liver biopsy is the gold standard applied to detect NASH and determine the stage of fibrosis, but its use is limited. There is a need for non‐invasive testing (NIT) techniques to identify patients considered at‐risk NASH (NASH with NAFLD activity score > 4 and ≥ F2 fibrosis). For NAFLD‐associated fibrosis, several wet (serological) and dry (imaging) NITs are available and demonstrate a high negative predictive value (NPV) for excluding those with advanced hepatic fibrosis. However, identifying at‐risk NASH is more challenging; there is little guidance on how to use available NITs for these purposes, and these NITs are not specifically designed to identify at‐risk NASH patients. This review discusses the need for NITs in NAFLD and NASH and provides data to support the use of NITs, focusing on newer methods to non‐invasively identify at‐risk NASH patients. This review concludes with an algorithm that serves as an example of how NITs can be integrated into care pathways of patients with suspected NAFLD and potential NASH. This algorithm can be used for staging, risk stratification and the effective transition of patients who may benefit from specialty care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseHumansLiverLiver CirrhosisFibrosisPredictive Value of TestsBiopsy

Stichwörter der Autor:innen

At-risknon-alcoholic steatohepatitisnon-invasive testing

Autor:innen und Institutionen

  • South Denver Gastroenterology, Englewood, Colorado, USA.
  • Houston Research Institute, Houston, Texas, USA.
  • Impact Research Institute, Waco, Texas, USA.
  • Henry Ford Hospital, Detroit, Michigan, USA.
  • Inova Fairfax Medical Campus, Falls Church, Virginia, USA.
  • Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Zobair Younossi

Zitieren

APA

Kugelmas, M., Noureddin, M., Gunn, N., Brown, K., Younossi, Z., Abdelmalek, M., & Alkhouri, N. (2023). The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis. Liver International. https://doi.org/10.1111/liv.15555

Vancouver

Kugelmas M, Noureddin M, Gunn N, Brown K, Younossi Z, Abdelmalek M, et al. The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis. Liver International. 2023. doi:10.1111/liv.15555

BibTeX
@article{Kugelmas2023,
  author = {Kugelmas, Marcelo and Noureddin, Mazen and Gunn, Nadege and Brown, Kimberly and Younossi, Zobair and Abdelmalek, Manal and Alkhouri, Naim},
  title = {The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis},
  journal = {Liver International},
  year = {2023},
  doi = {10.1111/liv.15555}
}
Kostenlos starten →